

Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Information for the public

Published: 17 January 2024

www.nice.org.uk

Olaparib (Lynparza) with bevacizumab (Avastin) is available on the NHS as a possible maintenance treatment for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. You can have it if your cancer:

- has completely or partially responded to first-line platinum-based chemotherapy with bevacizumab
- is advanced and
- has a mutation on the BRCA1 or BRCA2 gene or genomic instability, which means gene mutations are more likely.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on ovarian cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovacome](#) (0800 008 7054)
- [Target Ovarian Cancer](#) (0207 923 5475)
- [Cancer Research UK](#) (0808 800 4040)
- [Macmillan Cancer Support](#) (0808 808 0000)

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5685-2